- SPIRIT2- "An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain."
This study is evaluating the benefit of an oral investigational medicine co-administered with 2 FDA-approved oral medications compared with placebo for 24 weeks for the treatment of dysmenorrhea and non-menstrual pelvic pain (NMPP) associated with endometriosis.
- Boreas, “A randomized, double-blind, placebo-controlled, parallel-group, 52-week pivotal study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with Type 2 inflammation.”
We need volunteers who have experienced at least two flare-ups (exacerbations) of COPD within the past 12 months in spite of taking long acting respiratory inhalers. This study is evaluating an injection therapy as a possible means of reducing the frequency of COPD exacerbations.
- GALACTIC-1 - "A randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks."
Individuals with idiopathic pulmonary fibrosis (IPF) are needed for a 2 year study testing an inhaled investigational medicine that would be added to present therapy.